MiR-142 acts as a tumor suppressor in osteosarcoma cell lines by targeting Rac1

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Osteosarcoma (OS) exhibits a significant risk of relapse and metastasis despite treatment advances.
• A subset of OS patients shows poor response to conventional chemotherapy.
• Identifying novel therapeutic targets is crucial for improving OS patient outcomes.

Purpose of the Study:

• To investigate the role of microRNA-142 (miR-142) in osteosarcoma.
• To explore the relationship between miR-142 and Ras-related C3 botulinum toxin substrate 1 (Rac1) in OS.
• To evaluate the potential of miR-142 and Rac1 as therapeutic targets for OS.

Main Methods:

• Quantitative analysis of miR-142 and Rac1 expression in OS tissues and cell lines.
• Luciferase reporter assays to confirm direct targeting of Rac1 by miR-142.
• Loss- and gain-of-function experiments to assess miR-142's impact on OS cell behavior.
• Analysis of cell proliferation, invasion, cell cycle, E-cadherin, MMP2, and MMP9 expression.

Main Results:

• miR-142 expression was significantly downregulated, while Rac1 expression was upregulated in OS tissues and cell lines.
• miR-142 directly targets the 3'-untranslated region of Rac1, regulating its expression.
• miR-142 suppressed OS cell proliferation, invasion, and induced S-phase cell cycle arrest.
• miR-142 inhibited invasion by upregulating E-cadherin and downregulating MMP2 and MMP9.

Conclusions:

• miR-142 functions as a tumor suppressor in osteosarcoma.
• The miR-142/Rac1 axis represents a potential therapeutic strategy for osteosarcoma.
• Overexpression of miR-142 or knockdown of Rac1 may offer novel treatment options for OS.